Noqturina (Desmopressin)

Desmopressin, the active ingredient in Noqturina, is a vasopressin analog presented as an oral dosage form for oral administration. It selectively stimulates renal V2 receptors, enhancing water reabsorption and reducing urine output, and is indicated for central diabetes insipidus, nocturnal enuresis in children, and selected bleeding disorders such as mild hemophilia A and von Willebrand disease.

GNH USA supplies Noqturina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Desmopressin acts on the antidiuretic pathway and coagulation management, providing therapeutic benefit in several conditions.

- Central diabetes insipidus: reduces excessive urine output by increasing water reabsorption in the kidneys. - Nocturnal enuresis: decreases nighttime bedwetting episodes by concentrating urine. - Mild hemophilia A: raises plasma factor VIII levels to improve clot formation. - Von Willebrand disease: enhances von Willebrand factor release, supporting hemostasis.

Desmopressin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Nasal congestion: sensation of blocked nose. - Mild hyponatremia: low sodium without severe symptoms.

Serious or Rare Side Effects: - Severe hyponatremia: can cause seizures or coma. - Water intoxication: excessive fluid retention leading to edema. - Thromboembolic events: rare clot formation. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating Noqturina, several safety considerations should be observed.

- Monitor sodium: check serum sodium regularly, especially in patients at risk of hyponatremia. - Fluid restriction: limit fluid intake to ≤1.5 L/day during treatment to prevent water overload. - Renal function: assess kidney function before initiating therapy. - Concomitant drugs: avoid simultaneous use of other antidiuretic agents unless medically justified. - Pregnancy and lactation: use only if benefits outweigh risks; consult healthcare provider. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Desmopressin can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - NSAIDs: may potentiate antidiuretic effect and increase hyponatremia risk. - Carbamazepine: can reduce desmopressin efficacy by increasing renal clearance. - Diuretics (especially thiazides): synergistic effect on water retention leading to hyponatremia. - Anticoagulants (e.g., warfarin): may enhance bleeding risk when used for hemostatic indications.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may modestly increase risk of hyponatremia. - SSRIs: combined use can raise hyponatremia potential. - Alcohol: may exacerbate fluid balance disturbances.